Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma

BACKGROUND: Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells. METHODS: A prospective, nonrandomized, uncontrolled, open-label, and multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez, Yamirka, Concepción, Martha L., Amador, Yohan, Piriz, Angel, Rabassa, René, Leyva, Ariel, Arguelles, Odalys, Leblanch, Lisett, Moret, Sheyla, Rivero, Gilberto, Vasallo, Ana L., Martorell, Beatriz, Guerra, Pedro P., Valls, Ana R., Sánchez, Lisset, Saumell, Yaimarelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162878/
https://www.ncbi.nlm.nih.gov/pubmed/37152586
http://dx.doi.org/10.1155/2023/1496072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162878/
https://www.ncbi.nlm.nih.gov/pubmed/37152586
http://dx.doi.org/10.1155/2023/1496072

Ejemplares similares